The functional importance of C2 insert containing isoform of nonmuscle myosin II-C is not known. Results: During the neuritogenesis of Neuro-2a cells, NM II-C1C2 becomes predominant isoform of NM II-C. Decreasing NM II-C1C2 expression leads to shortening of neurites. Conclusion: NM II-C1C2 plays a role in the later stage of neuritogenesis. Significance: Understanding of functional importance of NM II-C1C2.
SUMMARY
The functional role of the C2 insert of nonmuscle myosin II-C (NM II-C) is poorly understood. Here, we report for the first time that the expression of the C2 insert containing isoform, NM II-C1C2 is inducible in Neuro-2a cells during differentiation both at mRNA and protein levels. Immunoblot and RT-PCR analysis reveal that expression of NM II-C1C2 peaks between days 3-6 of differentiation. Localization of NM II-C1C2 in Neuro-2a cells suggest that the C2 insert containing isoform is localized in the cytosol and along the neurites, specifically at adherance point to substratum. Inhibition of endogenous NM II-C1C2 using siRNA decreases the neurite length by 43% compared with control cells treated with nonspecific siRNA. Time lapse image analysis reveals that neurites of C2-siRNA treated cells have a net negative change in neurite length per minute, leading to a reduction of overall neurite length. During neuritogenesis, NM II-C1C2 can interact and colocalize with β1-integrin in neurites. Altogether, these studies indicate that NM II-C1C2 may be involved in stabilizing neurites by maintaining their structure at adhesion sites. _______________________________________ Neuritogenesis is powered mainly by two types of molecular motors: microtubuleassociated motors and actin-associated motors (1) . Microtubule based motors are essential for vesicular transport of building materials during neurite assembly whereas actin based motors are responsible for cell motility, neurite outgrowth and directionality of the growth cone (2) (3) (4) . Neurite sprouting, extension and branching in neuritogenesis are essential processes during development of the mammalian nervous system. Neurite sprouting results in the breakdown of neuroblast symmetry, and neurite extension is the resultant of two vectorial processes, mainly forward and backward velocity (1, 5) . Neuroblast symmetry is broken as a localized bud forms, and neurites sprout from buds on the cell surface. As cells differentiate, these neurites extend and form axons and dendrites. Actin microfilaments and actin-based motors are responsible for generation of the force which is required for neurite sprouting and extension (6) .
Several studies have been reported that implicate nonmuscle myosin IIs (NM IIs) 3 in neuritogenesis (7) (8) (9) (10) (11) . The number of members of the NM II family has grown due to the discovery of a new gene and alternative splicing of NM IIs. The functional importance of individual isoforms of NM II is being investigated both in vivo and in vitro in several laboratories (12) (13) (14) (15) (16) (17) . NM IIs belong to the conventional Class II myosins and are hexameric proteins composed of two heavy chains of 230 kDa and two pairs of light chains, referred as the 20 kDa regulatory myosin light chain (RLC 20 ) and the 17 kDa essential myosin light chain (ELC 17 ). These myosins form bipolar filaments that slide actin filaments to produce force or maintain tension which is needed to drive important cellular functions such as cell polarity, cell migration, and cytokinesis (18) (19) (20) . Studies from several laboratories revealed that three different genes: Myh9, Myh10, and Myh14 code for three isoforms of nonmuscle myosin heavy chain (NMHC) II-A, -II-B, and -II-C, respectively in mice (21) . Enzymatic activity of these NM IIs is regulated by phosphorylation and dephosphorylation of RLC 20 which are catalyzed by enzymes such as myosin light chain kinase (MLCK) and Rho kinase, and myosin phosphatase (22) (23) (24) (25) (26) (27) (28) .
Similar to NM II-B, the pre-mRNA of the NMHC II-C gene undergoes alternative splicing to generate four isoforms: NMHC II-C0,-C1,-C2, and -C1C2. These isoforms have been expressed as proteins and their biochemical properties have been studied in vitro. It has been reported that baculovirus expressed heavy meromyosin (HMM) II-C0 or -C1 has actin-activated MgATPase activity and can propel actin filaments following RLC 20 phosphorylation, whereas HMM II-C2 or -C1C2 are constitutively activated, independent of RLC 20 phosphorylation. C1 insert, encoding 8 amino acids, is widely expressed in a variety of tissues such as lung, liver, kidney and brain whereas expression of the C2 exon, encoding 41 amino acids is restricted to neuronal tissues in the mouse (29) (30) (31) . The functional importance of NM II-C protein both in vivo and in vitro has been reported (32, 33) , but that of individual isoforms of NM II-C is still incomplete. In an in vitro study, the C1 insert containing isoform was shown to be involved in cytokinesis in tumor cells (30) , whereas no functional study of the C2 insert containing isoform has been, so far, reported.
Here we report the first examination of neuritogenesis in the absence of the C2 insert containing isoform, NM II-C1C2. We show that inhibition of NM II-C1C2 causes several defects in neuritogenesis: shortening of neurite length, lack of neurite branching, and reduction in the number of neurites per cell. We demonstrate that these defects result from the failure of stable adherence of neurites to the substratum. We offer evidence that NM II-C1C2, which is the major isoform of NM II-C in differentiated neurons, interacts with β1-integrin during neuritogenesis. This interaction may delineate the relationship between stable adherence and neuritogenesis.
EXPERIMENTAL PROCEDURES
Identification and quantification of the C2 insert in mouse Neuro-2a cells-Total RNA from Neuro-2a cells was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA). 1 µg of isolated total RNA was reverse transcribed using random hexamers and the Gene-Amp RNA PCR core kit (Applied Biosystems, Branchburg, NJ, USA). The resulting cDNA was amplified by PCR using the primer sets flanking the C2 inserted region: forward primer (P1), To check genomic DNA contamination in RNA samples, we performed cDNA synthesis in the absence of reverse transcriptase, which was used as a negative control for RT-PCR experiment. Products generated by RT-PCR were analyzed on a 1.8% agarose gel. The slower migrating bands, 694 bp, were extracted from the gel and digested with (Pst I) which confirmed the insertion of the C2 insert. Sequences of primers flanking the C1 insert (P3 and P4), C1 and C2 insert sequence (P5 and P6), at the C2 insert junction (P7), or at the C1 insert junction (P8), NMHC II-A (P9 and P10), NMHC II-B (P11 by guest on May 3, 2016 http://www.jbc.org/ Downloaded from and P12) and GAPDH (P13 and P14) were as follows:
We used the same PCR program to amplify the amplicons for the above primers. We used primers P1 and P6 for real-time PCR to quantify the amount of NMHC II-C1C2 mRNA using Syber green PCR master mix kit (Applied Biosystems). The program includes an initial 10 min at 95 0 C, and then 40 cycles of 15 s at 95 0 C for denaturation and 1 min at 60 0 C for annealing and extension. Similar way, P9 and P10, and P11 and P12 were used to quantify NMHC II-A and -II-B mRNA, respectively. After each cycle a melting curve analysis was performed to check that no primer dimers or nonspecific products were formed. Fold induction of a gene was calculated according to published method (34) . constructs containing GFP-tagged full length  cDNA of mouse NMHC II-C0, -II-C1, -II-C2  and -II-C1C2 were Transfection efficiency for DNA and siRNA was estimated using a fluorescence microscope (Olympus IX-51) by visualizing the signal coming from a GFP plasmid and Alexa-488 tagged siRNA, respectively. DNA transfection was almost 60%. SiRNA could knockdown mRNA by >90% as detected by RT-PCR analysis within 24 h post transfection. For rescue experiment 24 h post 3'-UTR-siRNA treated cells were transfected GFP tagged NMHC II-C constructs, and the cells were cultured for an additional 72 h in DM. For immunostaining studies, Neuro-2a cells were grown on chamber slides (BD Bioscience, San Jose, CA, USA), and were fixed with 4% paraformaldehyde at room temperature for 30 min, permeabilized with 0.5% Triton X-100 for 10 min, and treated with 5% normal goat serum in PBS (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 60 min at room temperature followed by incubation with NMHC II-C2 (gift from Dr. Robert S Adelstein, NIH, USA) and β1-integrin (Santa Cruz Biotechnology), or Fascin (at 1:500 dilution, Santa Cruz Biotechnology) antibodies overnight at 4 0 C. To stain actin filament, Orgeon Green-labeled phalloidin (Invitrogen) was added at room temperature for 1 h. The secondary antibody, Alexa 594 goat anti-rabbit IgG and/or Alexa 488 goat anti-mouse IgG, was incubated with cells at room temperature for 1 h. Nuclei were counterstained with 4', 6-diamidino-2 phenylindole (DAPI) from Invitrogen. After by guest on May 3, 2016 http://www.jbc.org/ Downloaded from washing, chamber slides were mounted using a Prolong Gold antifade kit (Invitrogen). The images were collected using a Nikon C1 confocal microscope (Nikon, Tokyo, Japan). Electrophoresis, immunoblotting and immunoprecipitation-Extracts of Neuro-2a cells were prepared for SDS-PAGE as described previously (31) . Briefly, cells on tissue culture plates were washed twice with cold phosphatebuffered saline and directly lysed with Laemmli sample buffer. Proteins were separated by SDS-PAGE on 8% polyacrylamide Tris-glycine gels, transferred to a polyvinylidene difluoride membrane (Millipore Corporation, Billerica, MA, USA), and blocked in 5% nonfat milk and 0.05% Tween 20 in phosphate-buffered saline. The upper part of the blot was incubated with antibodies to the C2 amino acid sequence (0.27 µg/ml) of NMHC II-C, C-terminal sequence of NMHC II-A (Cell Signaling Technology, Danvers, MA, USA or gift from Dr. Robert S Adelstein), or C-terminal sequence of NMHC II-B (Cell Signaling) and the lower part of the blot was incubated with antibody to β-actin (Sigma) at 4 °C overnight, washed and then incubated with horseradish peroxidase-conjugated secondary antibodies against mouse or rabbit IgG (Thermo Fisher Scientific , Waltham, MA, USA) at room temperature for 1 h. Blots were treated with SuperSignal® West Femto luminol enhancer solution (Thermo Scientific). Luminescence signal was captured on Biomax MR film (Eastman Kodak Co., Rochester, NY). For immunoprecipitation, an extract of Neuro-2a cells was prepared using a buffer composed of 50 mM Tris-HCl (pH 8.0), 60 mM KCl, 10 mM MgCl 2 , 5 mM ATP, 4 mM EDTA, 1 mM dithiothreitol, 1% Nonidet P-40, 0.5 mM PMSF, and protease inhibitors (chymostatin, 1-chloro-3-tosylamido-7-amino-2-heptanone, L-(tosylamido-2-phenyl)-ethyl chloromethyl ketone, leupeptin, phenylmethylsulfonyl fluoride, aprotinin, benzamidine, and pepstatin A) from Sigma, at 4 °C. The lysates were sedimented at 10,000 x g for 10 min, and the supernatant was incubated with antibody specific to the C2 insert or β1-integrin as previously reported (36) . The immunoprecipitates were fractionated by SDS-PAGE on 8% polyacrylamide Tris-glycine gels, and subsequently, the blot was probed with either antibody specific to β1-integrin or the C2 insert, NMHC II-A, and NMHC II-B. Protein concentrations were determined using a protein assay kit (Bio-Rad, Hercules, CA, USA). Time lapse imaging-Time lapse imaging of neuritogenesis was performed using a Nikon Ti-E microscope supported by the NIS-D software (Nikon, Tokyo). Images were recorded every 5 min for 48 h for both nonspecific and C2-siRNA treated Neuro-2a cells using a CCD camera (Digital sight DS-Qi1MC, Nikon) supported by NIS-D program. All time lapse imaging was performed under 5% CO 2 and at 37 °C in a stage incubator. To record neuritogenesis, movies were made taking five frames per second for up to 28h, whereas for cytokinesis, movie was made taking two frames per second. Change of neurite length (CNL) per minute was calculated using an equation: CNL/minute = (L tn+1 -L tn )/(t n+1 -t n ), where (t n+1 -t n ) = 10, L tn , length of neurite at n th time point (t n ), and L tn+1 is the length of next time point (t n+1 ). Statistical analysis-Data were expressed as the mean ±SEM. Statistical significance was tested with one-way analysis of variance followed by the Bonferroni test. The differences were considered to be significant if p was < 0.05.
Plasmid constructs and siRNAs-Plasmid

RESULTS
Expression of the C2 inserted isoforms of NMHC II-C in differentiated Neuro-2a cellsJana et al. (31) reported that exon C2, encoding 41-aa in the mouse, was inserted into the loop 2 region of NMHC II-C due to alternative splicing of NMHC II-C pre-mRNA. This C2 insert was shown to be expressed only in mouse and human brain tissue. To further investigate the expression profile of the C2 insert and its biological significance, we used the mouse neuroblastoma cell line, Neuro-2a, which is a model for neuronal differentiation. The differentiation method (1.5% DMSO and 0.5% serum) used for Neuro-2a cells induced neuritogenesis: sprouting, neurite elongation and branching. Neurite length during neuritogenesis was quantified and shown in Supplemental Figure S1A and B. Using reverse transcriptase-PCR (RT-PCR) analysis with primers specific to the C2 insert, we found that the expression of C2 insert containing mRNA is inducible in Neuro2a cells during differentiation, as detected by generation of a 297 bp band (Fig. 1A) . We differentiated Neuro-2a cells till day 12, and during this period, expression of the C2 inserted NMHC mRNA showed differential expression. Quantification of C2 inserted NMHC II-C mRNA by real time PCR revealed that 3-6d post differentiated Neuro-2a cells had an almost 18±2 fold increase in expression compared with undifferentiated Neuro-2a cells (Fig. 1B) . The expression of both NMHC II-A and NMHC II-B mRNA remained unchanged during differentiation of Neuro-2a cells (Fig. 1A and B) . As shown in Supplemental Figure S2 , we found that no splicing into loop 2 of NMHC II-B occurred during the Neuro-2a differentiation. Although trace or small amount of splicing into loop 1 of NMHC II-B occurred in Neuro-2a cells, expression of the B1 insert remained unchanged during this time period of differentiation and its expression was less than 10% of total NM II-B. We did not observe alternative splicing of NMHC II-A in either loop (unpublished observation). We then examined the expression of NMHC II isoforms at the protein level, and also, quantified their relative difference in expression in the undifferentiated and differentiated Neuro-2a cells using ImageJ software. Figure 1C shows immunoblots probed with antibodies specific to NMHC II-A, -II-B, C2 insert and Actin. Quantification of band intensity of II-C2 immunoblot ( Fig. 1D ) by ImageJ software revealed that 6d post addition of differentiation medium (DM), Neuro-2a cells expressed 50±5 fold more II-C2 compared with undifferentiated cells. In contrast, the immunoblots detecting NMHC II-A and -II-B showed almost no change in the expression at the protein level (Fig. 1D ), correlating with their mRNA level, which showed no significant change between differentiated and undifferentiated Neuro-2a cells (Fig. 1B) . These results suggest that expression of NMHC II-A and -II-B both at mRNA and protein levels remains essentially unchanged, whereas the C2 insert containing NMHC II-C isoform (s) increases during differentiation of Neuro-2a cells. NMHC II-C1 and NMHC II-C1C2 are the major isoforms of NMHC II-C in Neuro-2a cells-We investigated the expression of another insert C1 in NMHC II-C mRNA which was shown to be expressed in neuronal tissue (31) . We found that the C1 insert was expressed in both undifferentiated and differentiated Neuro2a cells (panels 1 and 2 of Fig. 2A , lane 2 vs 3-7). As both inserts, C1 and C2, were detected during Neuro-2a differentiation, four possible NMHC II-C mRNA isoforms: NMHC II-C0 (with no insert), NMHC II-C1 (with only C1 insert), NMHC II-C2 (only C2 insert), and NMHC II-C1C2 (with both C1 and C2 inserts), could be expressed in Neuro-2a cells. Using different pairs of primers for NMHC II-C: flanking C1 and C2 exons, located within C1 and C2 exons, or spanning the C2 exon (see primer location in Table 1 ), we analyzed the abundance of each NMHC II-C isoform mRNA during the differentiation of Neuro-2a cells ( Using primers P1 and P2, flanking the C2 exon, RT-PCR generated one band of 571 bp in undifferentiated Neuro-2a cells and two bands of 694 and 571 bp in differentiated cells, suggesting that undifferentiated cells do not express the C2 containing isoform whereas differentiated cells do ( Fig. 2A, panel 2) . Hence, using these primer sets, we may conclude that Neuro-2a cells show the expression of both NMHC II-C1 and -II-C1C2. To confirm the presence of NMHC II-C1 and -II-C1C2, we designed primers specific for each isoform. For NMHC II-C1C2, primers P5 and P6 (located in the C1 and C2 inserts) were used for RT-PCR analysis. A band of 1374 bp was seen in differentiated Neuro-2a cells ( Fig. 2A,  panel 3 ). For NMHC II-C1, the reverse primer, P7 was located at the junction of the C2 insert region (spanning exons 15 and 16 of NMHC II-C, see Table 1 ) and the forward primer, P5 matched the sequence of the C1 insert. Using P5 and P7, RT-PCR generated a band of 1264 bp representing NMHC II-C1 ( Fig. 2A, panel 4) . Digestion with Pst1 enzyme confirmed the identity of the PCR bands (data not shown). To quantify the abundance of the two isoforms, we measured the PCR band intensity ( Fig. 2A , panel 2) using ImageJ software. Quantification revealed that 64.6± 4.1 % of total NMHC II-C was NMHC II-C1C2, and 35.4±4.1% was NMHC II-C1 at day 6 during differentiation ( Fig.  2B ). We used primers P8 (spanning the exons that flank the C1 exon) and P7, and P8 and P6 to check if NMHC II-C0 and NMHC II-C2 were expressed, respectively. Panel 5 and 6 rule out the expression of II-C0 and II-C2 as no band was seen in Neuro-2a cells, respectively. These data suggest that Neuro-2a cells express the NMHC II-C1C2 as the predominant isoform of NMHC II-C during differentiation. Designing small interfering RNA and measuring its specificity against NMHC II-C1 and -II-C1C2-We were then interested to study the functional importance of two isoforms, NM II-C1 and -II-C1C2, in Neuro-2a cells. We used small interfering RNA (siRNA) to knockdown the expression of each isoform. We designed siRNA in the sequence of the C2 insert to target NMHC II-C1C2 mRNA alone in differentiated Neuro-2a cells. To test whether NMHC II-C1C2 has a critical role in Neuro-2a differentiation, siRNA was transfected into Neuro-2a cells prior to the onset of differentiation. Figure 3A and C show that both endogenous NMHC II-C1C2 and ectopically expressed NMHC II-C1C2-GFP were down regulated at 24 h post transfection with siRNA in C2-siRNA treated cells compared with nonspecific siRNA treated cells. We quantified the percentage of inhibition in the expression of NM II-C1C2 protein by measuring the immunoblot band intensity and fluorescence intensity ( Fig. 3B and D) . C2-siRNA treatment led to a reduction of NM II-C1C2 by 90% of the endogenous level and by 80% after ectopic expression. Specificity of C2-siRNA was further confirmed by its inability to down regulate the expression of exogenous GFP tagged NMHC II-C1,-II-C0 (unpublished observation) or endogenous NMHC II-A and -II-B (Fig. 3A) . We checked the NMHC II-C1C2 mRNA level at 24-72h of post C2-siRNA transfection in Neuro2a cells (Supplemental Fig. S3 ). C1C2 mRNA was almost reduced by 90% at 24 h. We designed siRNA (C1-siRNA), covering the region between 1904 -1922 nucleotide of NMHC II-C mRNA, to deplete mRNA which doesn't contain the C2 exon both in the presence of growth medium (GM) or DM. RT-PCR and fluorescence microscopy were used to monitor endogenous NMHC II-C1 mRNA and exogenous protein levels of NM II-C1, respectively, in siRNA treated Neuro-2a cells. Supplemental Figure S4A shows that C1-siRNA specifically inhibited the expression of NMHC II-C1. Expression of GFP tagged NMHC II-C1C2 in siRNA treated Neuro-2a cells was not inhibited, suggesting that C1-siRNA specifically inhibited the expression of NMHC II-C1 (Supplemental Fig. S4B ). Lower expression of NMHC II-C1C2 leads to reduced neurite length-We focused on exploring the effect of suppressing each of the NMHC II-C isoforms in differentiated Neuro-2a cells on neurite length and number of neurites per cell during neuritogenesis. We observed that C2-siRNA against C2 exon had a substantial effect on neurite length, number of neurites per cell, and percentage of cells having no neurites compared with the effect of nonspecific siRNA (Fig. 3E) . We quantified neurite length at 3 and 6d after siRNA treatment. At 3d and 6d, the average length of neurites was 48.6 and 43.11 µm, respectively, in C2-siRNA treated cells, whereas neurite length was 81.11 and 101.7 µm, respectively, in nonspecific siRNA treated cells (Fig. 3F) . There was almost a 2-fold difference in the number of neurites per cell in C2-siRNA treated cells compared with nonspecific siRNA treated cells at 6d (p<0.05, Fig. 3G ). These observations reveal that the effects of C2-siRNA of decreasing C1C2 expression in differentiated cells account for the decrease in neurite length and number of neurites per cell. We tested whether each NM II-C isoform tagged with GFP could rescue NM II-C1C2 depleted cells to the siRNA. Plasmid DNA containing full-length NMHC II-C isoform and GFP was transfected into 24 h post siRNA treated cells, and cells were cultured for additional 72 h in DM. For this rescue experiment, we designed siRNA on 3′-untranslated region of NMHC II-C mRNA (3'-UTR siRNA), which inhibited both prevailing isoforms of NMHC II-C: -C1 and -C1C2, and at the same time, was unable to lower the mRNA coming from the NMHC II-C0, -C1, -C2, or -C1C2 GFP plasmids in cells. The phenotype of GFP expressing cells was analysed by phase contrast and fluorescence microscopy. The loss of major isoform, myosin II-C1C2, expression in Neuro-2a cells leads to shortening of neurite length, whereas in rescue cells expressing NMHC II-C1C2-GFP or -C2-GFP, loss of endogenous myosin II-C1C2 has little effect on neurite length (Fig. 4 A) . Figure 4A shows that unlike NMHC II-C2 or -C1C2-GFP transfected cells which showed neurites and localization of NMHC II-C2 or -C1C2-GFP in neurite at 96 h, NMHC II-C0 or -C1-GFP transfected cells showed almost no neurite. Figure 4B immunoblot confirms the absence of NMHC II-C1C2 at 96 h in the 3'-UTR siRNAtreated cells that were subsequently transfected with GFP alone (lane 1, panel 2), and the inability of 3'-UTR siRNA in lowering the amount of NMHC II-C-GFPs encoded by NMHC II-C-GFP plasmid DNAs (lane 2-5, panel 1 and 2). Blots also reveal that approximately equal amount of each isoforms was expressed in siRNA-treated cells (lane 2-5, panel 1 and 2). We quantified the effect of NMHC II-C-GFP in II-C knockdown cells (Table 2) , considering the cells that possess more than two neurites, and less than two neurites. Both population of cells were increased in NMHC II-C2 and NMHC II-C1C2 transfected cells. Only 5-7% of GFP positive cell showed more than two neurites in only GFP plasmid transfected cells. In contrast, around 27% of NMHC II-C1C2-GFP or -C2-GFP positive cells showed more than two neurites compared with 5-8% of NMHC II-C0 or -C1-GFP positive cells. We also quantified the length of neurites in NMHC II-C-GFP positive cells. Table 2 shows that GFP alone positive cells have neurite length around 8 µm. In contrast, NMHC II-C1C2-GFP or -C2-GFP positive cells showed neurites of around 40 µ m compared with NMHC II-C0, -C1-GFP which showed neurite length around 7 µm. We next separately inhibited the expression of NMHC II-C1 by >90 % using an siRNA spanning neucleotide region from 1904 to 1922 of NMHC II-C mRNA (Table 1 , Supplemental Fig. S4A-D) , and that inhibition resulted in failure of cytokinesis in Neuro-2a cells, similar to a previous finding in human A549 cells (30) . C1-siRNA treated cells showed normal neuritogenesis but incomplete cytokinesis (Supplemental Movie 1 and Fig. S4B and E) . Quantification revealed that nearly 14% cells failed in cytokinesis, 58% cells showed normal neuritogenesis and almost 28% cells were round shape in C1-siRNA treated Neuro-2a cells (Supplemental Fig. S4F ). These data suggest that C2 insert containing isoforms: NM II-C2 or NM II-C1C2, but not non-C2 insert isoforms: NM II-C0 or NM II-C1, are involved in neuritogenesis. Inhibition of NMHC II-C1C2 interferes with a late stage of neuritogenesis in Neuro-2a cellsShortening of neurite length and decrease in neurite number by C2-siRNA suggested that the C2 insert containing isoform plays a role in neuritogenesis. Microscopy detected that a large percentage of the cells treated with C2 exon specific siRNA rounded up or had one/two neurites compared with control cells treated with nonspecific siRNA. This suggested that NMHC II-C1C2 knockdown cells either lost neurite adhesion or increased retrograde flow or both. To analyze neuritogenesis in detail, time lapse imaging over a 48 h period at 5 min intervals was performed after addition of DM to cells that had been previously treated with siRNA for 24 h.
For this experiment, we tracked cells' neurites (n>10 cells) for each siRNA treatment. We made comparisons of neurites in nonspecific and C2-siRNA treated cells that extended and/or then retracted neurites to make sure that we were measuring neuritogenesis. As an increase or decrease of neurite length was associated with either neurite outgrowth, retrograde, or cell body movement, or combination of factors, we measured the change of neurite length (CNL) per minute during the process of neuritogenesis. CNL/minute was calculated by dividing the change of distance by a neurite by the time taken for such change. indicates shortening of neurite length. In contrast to neurite of nonspecific siRNA treated cells, neurite of C2-siRNA treated cells (Fig. 5B, D and Supplemental Movie 3) showed that CNL/min followed cyclic pattern with amplitude value from (+) 1.7 to (-) 1.13 µm/min, but after 8-10 h of neuritogenesis, the amplitude values were reduced to (+) 0.26, and to (-) 0.3 µm/min, respectively. We measured net CNL/minute (average of all positive value + average of all negative value) of total >10 neurites before and after the 8-10 h period during neuritogenesis, and found that neurites of nonspecific siRNA treated cells increase their length at 0.217 ± 0.04 µm/min and 0.117 ± 0.007 µm/min during early and later stage of neuritogenesis, respectively, whereas neurites of C2-siRNA treated cells increase their length at 0.16 ± 0.003 µm/min during the early phase, but reduce their length at -0.06 ± 0.01 µm/min during the later stage of neuritogenesis ( Fig. 5E and F) . Difference of net CNL/minute between nonspecific and C2-siRNA was statistically significant at later stage of neuritogenesis. In our culture system, neuritogenesis followed a well defined stereotyped program: stage 1 within a few hours (0-2 h after changing to DM) of neuritogenesis, most cells started sprouting but were devoid of neurites, stage 2 within 2-4 h of neuritogenesis, neurons developed neurites and depending on the number of neurites, cells' morphology could be divided into groups like unipolar, bipolar, and multipolar, but none with established axon, stage 3 after 4 h of neuritogenesis, neurites started to grow and form axons, and the remaining neurites could not extend during this stage consistent with similar observation by de Lima et al. (37) . In control cells treated with nonspecific siRNA, we found that stage 1 and stage 2 were interchangeable (Fig. 6A) , and in stage 2 polarity changed reversibly, bipolar to multipolar and vice versa. In stage 3, neurons changed axonal position, meaning the axon became a neurite and another neurite became an axon which we termed as stage 3A (Fig. 6B) . We found that Neuro-2a cells treated with nonspecific siRNA showed an increase in neurite length at a net rate of 0.217 µm/min and reached a length 112 µm within 10 h (Fig. 5E ). Both movie (Supplemental Movie 2) and images (Fig. 5A) show that nonspecific siRNA treated cell bodies and neurites undergo retrograde and forward movement even after 24 h. C2 exon specific siRNA treated Neuro-2a cells (n>14) also formed neurites and reached the same maximum length as control cell neurites (Fig. 5B) . Unlike control cells, the neurites started shortening at a rate -0.06±0.01 µm/min after 8-10 h (Fig. 5F) , the time point when expression of NM II-C1C2 reached a maximum level in control cells (Figure 2, panel 2 ). 28 h after neuritogenesis, no neurite was seen, and cells became round. Thus, adhesion of the cell body, and retrograde flow depend on myosin II-C1C2, which is the major isoform of NM II-C, during neuritogenesis. As no conversion of stage 3 to 3A was involved, rather stage 3 returns to stage 1, in NMHC II-C1C2 knockdown cells, NM II-C1C2, but not NM II-C1, may be involved in maintaining the stability of stage 3 and/or conversion from stage 3 to 3A.
Localization of Myosin II-C1C2 during neuritogenesis-Time lapse imaging analysis established that NM II-C1C2 may play role in the stability of stage 3 of neuritogenesis, which prompted us to study the localization of NMHC II-C1C2 in Neuro-2a cells during neuritogenesis. Supplemental Figure S5 shows that NMHC II-C1C2 initially localizes at sprouts at 24 h, and then in the neurite and neurite tip at 72 h post differentiation. Other isoforms NMII-C1, -II-A and -II-B are distributed throughout the cell body and neurites of Neuro-2a cells during neuritogenesis (Supplemental Figure S5) . This observation suggests that the C2 insert is responsible for the observed localization pattern for NM II-C1C2. It had been reported that blocking of myosin activity by pharmacological drugs modulates integrin and the extracellular matrix (38). As β1-integrin is involved in adhesion of neuronal cells during neuritogenesis (39-41), we were interested to see which isoform of NM II can interact with β1-integrin. The immunoblot (Fig.7A) (Fig.  7C) . Figure 7D shows that both at day 3 and 6 post differentiation NM II-C1C2 colocalizes with β1-integrin in 6d, suggesting that NM II-C1C2 may play a role in the adhesion of neurites to the substratum as the neurites mature during later stages of neuritogenesis. Shortening of filopodial length-Filopodia play a significant role in neurite protrusion (42,43). We used actin staining to visualize filopodia following inhibition of NM II-C1C2 protein in Neuro-2a cells during differentiation. Figure 8A shows that NM II-C1C2 depletion greatly inhibited the number of filopodia across the neuronal shaft and cell body. We quantified the number of filopodia per cell > 5 µ m in length and spread along the leading edge, cell body and neuronal shaft, between nonspecific and C2-siRNA treated cells (Fig. 8B) . Nonspecific siRNA treated cells showed 28.3±2.9 filopodia per cell whereas C2-siRNA treated cells showed only 3.1±1.2. We also used filopodia markerfascin and VASP staining and found decreased number of both lateral and dorsal filopodia in C2-siRNA treated cells compared with nonspecific siRNA treated cells (Supplemetal Figure S6 C and E). Inhibition of NMHC II-C1C2 expression did not interfere in the expression of both fascin and VASP (Supplemetal Figure S6 A-B) . Interestingly, Ectopic expression of GFP tagged NMHC II-C1C2 rescued the decreased number of filopodia in NM II-C1C2 knockdown Neuro-2a cells (Supplemetal Figure S6 D) . Taken together, our data may suggest that integrin-myosin dependent stable adhesion complexes in neurites are required for filopodia formation.
DISCUSSION
In this study, we uncovered essential requirements for NM II-C1C2 during neuritogenesis. We found that inhibition of NM II-C1C2 expression caused a decreased outgrowth of neurites, and reduced the number of filopodia in differentiated Neuro-2a cells. Focal adhesion (FA) complex composition is modulated by myosin II activity (44), and changes in FA composition are necessary to modulate integrin mediated cell signaling for differentiation. Of note, during differentiation of Neuro-2a cells, the composition of NM II-C has also been remarkably changed from a myosin light chain phosphorylation dependent NM II-C1 to phosphorylation independent NM II-C1C2 isoform. Switching of these isoforms arises due to alternative splicing which is regulated during differentiation. Furthermore, we had also analyzed the splicing of NM II-B and found that only the B1, but not the B2 insert is present in the heavy chain of NM II-B in these cells. Expression of B1 is very low, likely 10% of total NM II-B, and remains essentially unchanged during neuritogenesis (Supplemental Fig. S2 ). Integrin-mediated focal adhesions play an important role in cell adhesion, cytoskeleton reorganization and the signaling that controls cell division, differentiation, and migration. Recently, it has been documented that during cell migration, the composition of FAs changes in response to tension during FA maturation from nascent to mature, and is modulated by nonmuscle myosin II activity in human foreskin fibroblast cells, HFF1 (44). There are two hypotheses for how NM II mediates adhesion maturation. NM II bundles actin filaments and as a consequence adhesion proteins are brought together and clustered. This event increases molecular interaction between adhesion proteins, resulting in increased integrin avidity for ligand, and signaling. In second hypothesis, NM II generates force that induces conformational changes in adhesion-associated molecules and non-mechanosensitive signaling molecules (45). Although our data does not favor one hypothesis over the other, our results do show evidence for a possible interaction between β1-integrin and the C2 insert containing isoform of NM II-C under the low serum/DMSO differentiation condition. Our result allow us to hypothesize that integrin-NM II-C1C2 dependent stable adhesion complexes in neurites can help the dendritic network of actin to reorganize into bundles of long filaments. Activities of Ena/VASP (46), fascin (47), formin (48), Arp2/3 by guest on May 3, 2016 http://www.jbc.org/ Downloaded from complex and Rho GTPases (RhoA-Kinase) (49-51) may be responsible for this process. This stable adhesion complex may be involved in maintaining filopodial length. We hypothesize that punctate localization of NM II-C1C2 in the neurite (Supplementary Fig. S5 ) may be responsible for generating stable adhesion by making complexes with integrin that stabilize the neurites during the later stage of neuritogenesis. Rosado et al. (52) have recently shown that NM II-A associates with the cytoplasmic domain of α4 subunit of the α4β1-integrin and regulates cell migration in CHO cells. Although it remains unclear whether myosin and integrin association is due to direct binding or through other proteins, both studies support a notion that interaction between NM II and integrin is involved in cell-matrix adhesion. Inhibition of C2 insert containing isoforms does not interfere with neurite initiation, implying that NM II-C1C2 may not be required for symmetry breaking of neurospheres, although exogenous GFP tagged NM II-C1C2 could localize to the initiation site, the place where the neuroblast sphere would be broken to make the first neurite (Supplemental Information Fig. S5 ). It is important to note that neurons having lowered amounts of NM II-C1C2 do form axons, and extend to a maximum length, but are not stabilized for long periods of time. We hypothesize that neurite growth displays biphasic speed (retrograde phase with a negative CNL value and protrusion phase with a positive value) during neuritogenesis. The neurite final length is dependent on the relative duration of the two phases. At a later stage of neuritogenesis, neurites of C2-siRNA treated Neuro-2a cells pass through a retrograde phase, which leads to shortening of their length. NM II-C knockout mice show no obvious defect in the brain (32) . This difference with our in vitro result may reflect the complexity of the mammalian brain. Possibly, other isoforms of NM II-C compensate for the loss of NM II-C1C2, or the cells are exposed to external cues that bypass the requirement for NM II-C1C2. All isoforms of NM II, including possible alternatively spliced isoforms of NM II-B and -II-C, are found in neuronal cells (31, 33, 43) , giving rise to complexity as to whether these isoforms have different or redundant functions in neuronal cells. Previously, NM II-C was shown to be involved in multitasking in neuronal cells (33) . Neurite outgrowth, adhesion, retraction and cell spreading are affected by the NM II-C isoform. NM II-C shares a functional role with NM II-B in neurite outgrowth, and with NM II-A and II-B in adhesion but has unique features distinct from either NM II-A or -II-B in cell spreading and in neurite retraction.
The previous study did not analyze the isoform specificity of NM II-C. Our study supports the idea that the C2 insert containing isoform, NM II-C1C2 is involved in neuritogenesis and the C1 insert containing isoform, NM II-C1 participates in cytokinesis of neuronal cells. We used DMSO/low serum to induce neuritogenesis, in which alternative splicing of NMHC II-C, but not of NMHC II-B or -II-A, occurred at loop 2 of its motor domain. Interestingly, we could not detect the expression of the C2 insert when Neuro-2a cells were induced to differentiate in the presence of retinoic acid or nerve growth factor (unpublished observation). Previously,Seidman et al. (35) have shown that DMSO/low serum induced the expression of the angiotensin type 2 receptor, AT2 in neuroblastoma cells, NG108-15. The brain AT system has been shown to be involved in learning and memory as well as growth and development (53-56). We are now further investigating the importance of the C2 insert containing isoforms of NM II-C in this physiological process. DM, lane 3-7) was subjected to RT-PCR analysis for NMHC II-C isoforms using primers specific for each NMHC II-C isoform. The panels (A) show the expression of each isoform of NMHC II-C, as indicated in a representative gel. GAPDH was used as a control for cDNA in the PCR. Plasmid DNA encoding NMHC II-C0 or NMHC II-C2 (lane 8) was used as positive control for PCR in panels 5 and 6. Note that C1 and C1C2 mRNA are the major isoforms expressed in 3-6 day differentiated Neuro-2a cells. (B) Quantification of C1 and C1C2 mRNA was expressed as a percentage of total NMHC II-C mRNA ( see second panel from top in a). (%) of an isoform=(intensity of band corresponding to an isoform/total intensity of two bands generated using C2 flanking primers) X 100. Band intensity was measured using ImageJ software. Note that the NMHC II-C1C2 population is increased with differentiation whereas that of NMHC II-C1 decreased. Results are expressed as mean ± SEM from three independent experiments. d, days. 
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Immunoblotting and immunostaining-Extracts of Neuro-2a cells were prepared for SDS-PAGE as described in Experimental Procedure section. The upper part of the blot was incubated with antibodies to the C2 amino acid sequence (0.27 µg/ml) of NMHC II-C, and the lower part of the blot was incubated with antibody to Fascin (Santacruz Biotechnology), VASP (Cell Signaling) or β-actin (Sigma) at 4 °C overnight, washed and then incubated with horseradish peroxidase-conjugated secondary antibodies against mouse or rabbit IgG (Thermo Fisher Scientific , Waltham, MA, USA) at room temperature for 1 h. Blots were treated with SuperSignal® West Femto luminol enhancer solution (Thermo Scientific). Luminescence signal was captured on Biomax MR film (Eastman Kodak Co., Rochester, NY). For filopodial staining, Neuro-2a cells were grown on chamber slides (BD Bioscience), and were fixed with 4% paraformaldehyde at room temperature for 30 min, permeabilized with 0.5% Triton X-100 for 10 min, and treated with 5% normal goat serum in PBS (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 60 min at room temperature followed by incubation with Fascin (at 1:500 dilution ) or VASP (at 1:500 dilution) antibodies overnight at 4 0 C followed by Orgeon Green-labeled phalloidin (Invitrogen) at room temperature for 1 h. The secondary antibody, Alexa 594 goat anti-rabbit IgG or Alexa 594 goat antimouse IgG, was incubated with cells at room temperature for 1 h. After washing, chamber slides were mounted using a Prolong Gold antifade kit (Invitrogen). The images were collected using a Nikon C1 confocal microscope (Nikon, Tokyo, Japan). Figure S1 . Differentiation of the mouse neuroblastoma cell line Neuro-2a. Neuro-2a cells were grown on a plastic tissue culture-treated surface without any coating and differentiated in the presence of 1.5% DMSO and 0.5% fetal bovine serum in DMEM, and images of differentiated cells were captured at 1 day interval till 12 days (A). Neurite length was measured using ImageJ software and quantified in (B). Scale bar: 50 µm; d, days. 
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